April 11, 2022. In light of the ongoing opioid epidemic, we commend FDA’s goal of fostering the development of non-addictive alternatives to opioids for managing acute pain, and thereby decreasing exposure to opioids and preventing new addiction.
Read More »Tag: clinical trial design
NCHR’s Testimony to FDA on Pediatric Development Plans for Oncology Indications
When evaluating drugs for pediatric use, doses must be scrutinized cautiously for children of different ages and weights. Even when there are likely benefits for children on average, it is important to minimize risks whenever possible by determining which children are most and least likely to benefit.
Read More »